These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19228862)

  • 1. Predictors and impact of intensification of antihyperglycemic therapy in type 2 diabetes: translating research into action for diabetes (TRIAD).
    McEwen LN; Bilik D; Johnson SL; Halter JB; Karter AJ; Mangione CM; Subramanian U; Waitzfelder B; Crosson JC; Herman WH
    Diabetes Care; 2009 Jun; 32(6):971-6. PubMed ID: 19228862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Associated with Diabetes-Related Clinical Inertia in a Managed Care Population and Its Effect on Hemoglobin A1c Goal Attainment: A Claims-Based Analysis.
    Ruiz-Negrón N; Wander C; McAdam-Marx C; Pesa J; Bailey RA; Bellows BK
    J Manag Care Spec Pharm; 2019 Mar; 25(3):304-313. PubMed ID: 30816810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
    Mocarski M; Yeaw J; Divino V; DeKoven M; Guerrero G; Langer J; Thorsted BL
    J Manag Care Spec Pharm; 2018 Apr; 24(4):390-400. PubMed ID: 29406841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents.
    Kim K; Unni S; McAdam-Marx C; Thomas SM; Sterling KL; Olsen CJ; Johnstone B; Mitchell M; Brixner D
    J Manag Care Spec Pharm; 2019 Mar; 25(3):314-322. PubMed ID: 30816811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of an Electronic Medical Record (EMR) to Identify Glycemic Intensification Strategies in Type 2 Diabetes.
    Korytkowski MT; Brooks M; Lombardero M; DeAlmeida D; Kanter J; Magaji V; Orchard T; Siminerio L
    J Diabetes Sci Technol; 2015 May; 9(3):593-601. PubMed ID: 25526759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycemic response to newly initiated diabetes therapies.
    Karter AJ; Moffet HH; Liu J; Parker MM; Ahmed AT; Go AS; Selby JV
    Am J Manag Care; 2007 Nov; 13(11):598-606. PubMed ID: 17988185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensification of Diabetes Therapy and Time Until A1C Goal Attainment Among Patients With Newly Diagnosed Type 2 Diabetes Who Fail Metformin Monotherapy Within a Large Integrated Health System.
    Pantalone KM; Wells BJ; Chagin KM; Ejzykowicz F; Yu C; Milinovich A; Bauman JM; Kattan MW; Rajpathak S; Zimmerman RS
    Diabetes Care; 2016 Sep; 39(9):1527-34. PubMed ID: 27519447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensification of antihyperglycemic therapy among patients with incident diabetes: a Surveillance Prevention and Management of Diabetes Mellitus (SUPREME-DM) study.
    Raebel MA; Ellis JL; Schroeder EB; Xu S; O'Connor PJ; Segal JB; Butler MG; Schmittdiel JA; Kirchner HL; Goodrich GK; Lawrence JM; Nichols GA; Newton KM; Pathak RD; Steiner JF
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):699-710. PubMed ID: 24639086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary language, income and the intensification of anti-glycemic medications in managed care: the (TRIAD) study.
    Duru OK; Bilik D; McEwen LN; Brown AF; Karter AJ; Curb JD; Marrero DG; Lu SE; Rodriguez M; Mangione CM
    J Gen Intern Med; 2011 May; 26(5):505-11. PubMed ID: 21174165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do patient or provider characteristics impact management of diabetes?
    LeBlanc ES; Rosales AG; Kachroo S; Mukherjee J; Funk KL; Nichols GA
    Am J Manag Care; 2015 Sep; 21(9):597-606. PubMed ID: 26618363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine.
    Rosenstock J; Eliaschewitz FG; Heilmann CR; Muchmore DB; Hayes RP; Belin RM
    Diabetes Technol Ther; 2009 Sep; 11 Suppl 2():S63-73. PubMed ID: 19772451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors and Clinical Outcomes of Treatment Intensification in Patients With Type 2 Diabetes Uncontrolled on Basal Insulin in a Real-World Setting.
    Kallenbach L; Shui AM; Cheng WY; Fan T; Hu W; Zichlin ML; Duh MS; Ye F; Levin PA
    Endocr Pract; 2018 Sep; 24(9):805-814. PubMed ID: 29975575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized Care and the Role of Insulin as a Vehicle to Optimizing Treatments in Diabetes Care.
    Bieszk N; Grabner M; Wei W; Barron J; Quimbo R; Yan T; Biel B; Chu JW
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1160-1168. PubMed ID: 29083969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management.
    Grant R; Adams AS; Trinacty CM; Zhang F; Kleinman K; Soumerai SB; Meigs JB; Ross-Degnan D
    Diabetes Care; 2007 Apr; 30(4):807-12. PubMed ID: 17259469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Foregone Opportunities? Time to Treatment Intensification Among Adults With Type 2 Diabetes and Elevated Glycated Hemoglobin on Metformin Monotherapy, 2009-2018.
    Lau D; Eurich DT; Simpson SH
    Can J Diabetes; 2022 Apr; 46(3):238-243.e4. PubMed ID: 35568424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy.
    Riedel AA; Heien H; Wogen J; Plauschinat CA
    Pharmacotherapy; 2007 Aug; 27(8):1102-10. PubMed ID: 17655510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.
    Blicklé JF; Hancu N; Piletic M; Profozic V; Shestakova M; Dain MP; Jacqueminet S; Grimaldi A
    Diabetes Obes Metab; 2009 Apr; 11(4):379-86. PubMed ID: 19087105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%.
    Pani LN; Nathan DM; Grant RW
    Diabetes Care; 2008 Mar; 31(3):386-90. PubMed ID: 18083790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Real-World Observational Study of Time to Treatment Intensification Among Elderly Patients with Inadequately Controlled Type 2 Diabetes Mellitus.
    Ajmera M; Raval A; Zhou S; Wei W; Bhattacharya R; Pan C; Sambamoorthi U
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1184-93. PubMed ID: 26679967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.